Stonewise
2 known investors
Stonewise develops MolVado, an AI-driven platform for small-molecule drug discovery that uses multimodal 3D molecular generation models to design candidate molecules based on protein pockets, reference fragments, or pharmacophores. The platform supports the full DMTA (Design-Make-Test-Analyze) cycle, combining generative AI with computational chemistry validation tools and a compound library backed by CRO synthesis services for pharmaceutical R&D teams.
AI & Machine LearningBiotechDeep Tech